Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT): a Randomised Controlled Trial

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The study would enrolled a total of 2100 AMI patients undergoing PCI to one of three antithrombotic regimens: bivalirudin alone, or unfractionated heparin alone, or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. All enrolled patients would be followed-up to 30 days, 6 months, and 1 year. The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES.
Epistemonikos ID: bb81c72bb3257aaee82f9781d941ab77ea350ab5
First added on: May 11, 2024